ā¢
SG
SGHT
Sight Sciences, Inc. Common Stock
polygonSURGICAL & MEDICAL INSTRUMENTS & APPARATUS
--
Price Chart
Market Cap
329.92M
Volume
326.32K
52W High
$9.24
52W Low
$2.03
Open
$6.28
Prev Close
$6.24
Day Range
6.18 - 6.44
About Sight Sciences, Inc. Common Stock
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
Latest News
UnitedHealthcare Adds Sight Sciences OMNI System To Covered Glaucoma Surgery Procedures
Benzingaā¢Sep 9
Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCareĀ® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease
GlobeNewswire Inc.ā¢Jul 30
Sight Sciences Announces the Publication of the 24-Month Results of the SAHARA RCT Demonstrating the Durability of the TearCareĀ® Procedure for the Treatment of Dry Eye Disease
GlobeNewswire Inc.ā¢Jul 29
Dry Eye Treatment Devices Market Poised to Attain Valuation of US$ 898.78 Million By 2033 | Pharmacological Synergy Driving Demand for Advanced Dry Eye Treatment Devices Says Astute Analytica
GlobeNewswire Inc.ā¢Feb 10
Sight Sciences to Report Second Quarter Financial Results on August 1, 2024 - GlobeNewswire
GlobeNewswire Inc.ā¢Jul 18
Sight Sciences CFO Alison Bauerlein sells over $65k in company stock By Investing.com - Investing.com
Investing.comā¢Jul 4
Sight Sciences Announces the Release of its First Sustainability Report
GlobeNewswire Inc.ā¢Jun 10
Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis
GlobeNewswire Inc.ā¢May 28